Ability of a synthetic Aluminium-Magnesium Silicate [AMS] to inhibit activities of canine parvovirus [CPV] was investigated in vitro and in vivo. Five samples of CPV isolated in Nigeria, were each incubated with equal...Ability of a synthetic Aluminium-Magnesium Silicate [AMS] to inhibit activities of canine parvovirus [CPV] was investigated in vitro and in vivo. Five samples of CPV isolated in Nigeria, were each incubated with equal amount of a synthetic AMS on a volume to weight [v/w] basis, for one hour and then centrifuged. Viral titres of the supernatants were tested by the haemagglutination [HA] test and their mean titre compared with mean titre of portions of same viral samples, not incubated with the AMS. Also, five puppies and five adult dogs infected with the parvovirus isolates were treated by dosing each with 400 mg/kg of a drug formulation that has 12% AMS per os for seven days. As control, five puppies and five adult dogs from same class as the experimental dogs were similarly infected but were not treated. Incubating parvovirus with AMS reduced its load from mean HA titre 825.6 ± 261.1 to mean HA, 270.8 ± 132.1 [p < 0.05]. Also treating parvovirus infected dogs with a 12% AMS drug formulation reduced mortality due to the virus from 100% to zero [p < 0.01].展开更多
文摘Ability of a synthetic Aluminium-Magnesium Silicate [AMS] to inhibit activities of canine parvovirus [CPV] was investigated in vitro and in vivo. Five samples of CPV isolated in Nigeria, were each incubated with equal amount of a synthetic AMS on a volume to weight [v/w] basis, for one hour and then centrifuged. Viral titres of the supernatants were tested by the haemagglutination [HA] test and their mean titre compared with mean titre of portions of same viral samples, not incubated with the AMS. Also, five puppies and five adult dogs infected with the parvovirus isolates were treated by dosing each with 400 mg/kg of a drug formulation that has 12% AMS per os for seven days. As control, five puppies and five adult dogs from same class as the experimental dogs were similarly infected but were not treated. Incubating parvovirus with AMS reduced its load from mean HA titre 825.6 ± 261.1 to mean HA, 270.8 ± 132.1 [p < 0.05]. Also treating parvovirus infected dogs with a 12% AMS drug formulation reduced mortality due to the virus from 100% to zero [p < 0.01].
